Related Experiment Video

Updated: Feb 9, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K

Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction

Kieran F Docherty1, John J V McMurray1

  • 1Institute of Cardiovascular & Medical Sciences, University of Glasgow, Scotland, UK.

International Journal of Cardiology
|June 13, 2018
PubMed

Insights

Sacubitril/valsartan, a novel heart failure medication, significantly reduces cardiovascular death and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). This ARNI therapy offers improved outcomes compared to traditional ACE inhibitors.

Area of Science:

  • Cardiology
  • Pharmacology
  • Heart Failure Research

Background:

  • Despite advances, heart failure with reduced ejection fraction (HFrEF) patients face high cardiovascular risks.
  • Current therapies, while improved, still leave a significant unmet need for better outcomes.

Purpose of the Study:

  • To review the development and evidence for sacubitril/valsartan, a novel angiotensin receptor-neprilysin inhibitor (ARNI).
  • To discuss the current and future role of sacubitril/valsartan in managing HFrEF.

Main Methods:

  • Review of the PARADIGM-HF trial, a large, phase 3, randomized controlled trial.
  • Comparison of sacubitril/valsartan against enalapril, a standard angiotensin-converting enzyme inhibitor.

Main Results:

  • Sacubitril/valsartan demonstrated a significant reduction in cardiovascular death or heart failure hospitalization compared to enalapril.
  • The drug also showed improvements in symptoms for patients with chronic, symptomatic HFrEF.

Conclusions:

  • Sacubitril/valsartan represents a significant advancement in HFrEF management.
  • This ARNI therapy is a valuable new option for improving patient outcomes and reducing adverse cardiovascular events.

Keywords:
Angiotensin receptor-neprilysin inhibitorHeart failureHeart failure with reduced ejection fractionNatriuretic peptidesNeprilysinRenin-angiotensin aldosterone system

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
978
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
927
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.7K